Gillies W E, Brooks A M
Royal Victorian Eye and Ear Hospital, Melbourne, Australia.
Ophthalmic Surg Lasers. 1998 Sep;29(9):728-32.
To determine whether the effectiveness of dorzolamide changes when the drug is used under routine clinical conditions versus the more ideal conditions of a clinical trial.
A total of 118 eyes of 65 patients were assessed. Nine patients (15 eyes) received dorzolamide only, 41 patients (74 eyes) received dorzolamide as an "add-on" medication, and 15 patients (29 eyes) received dorzolamide as a substitute for an oral carbonic anhydrase inhibitor.
At 1 month the intraocular pressure (IOP) had decreased from 23.5 to 19.9 mm Hg in the patients receiving dorzolamide only, from 18.6 to 16.4 mm Hg in the patients receiving dorzolamide as an add-on medication, and from 17.7 to 16.0 mm Hg in the patients receiving dorzolamide as a substitute for an oral carbonic anhydrase inhibitor. Similar decreases in IOP were present at 3 and 6 months. Local drug reactions occurred in 3 patients. Five patients stopped treatment because of severe symptoms of nausea and prostration.
Under routine clinical conditions, dorzolamide was effective as a sole medication and as an add-on medication. It was at least as effective as oral acetazolamide. Local drug reactions sometimes occurred, as did systemic reactions.
确定多佐胺在常规临床条件下使用时与在更理想的临床试验条件下使用时，其疗效是否会发生变化。
共评估了65例患者的118只眼睛。9例患者（15只眼睛）仅接受多佐胺治疗，41例患者（74只眼睛）接受多佐胺作为“附加”药物治疗，15例患者（29只眼睛）接受多佐胺替代口服碳酸酐酶抑制剂治疗。
仅接受多佐胺治疗的患者，1个月时眼压从23.5毫米汞柱降至19.9毫米汞柱；接受多佐胺作为附加药物治疗的患者，眼压从18.6毫米汞柱降至16.4毫米汞柱；接受多佐胺替代口服碳酸酐酶抑制剂治疗的患者，眼压从17.7毫米汞柱降至16.0毫米汞柱。3个月和6个月时眼压也有类似程度的下降。3例患者出现局部药物反应。5例患者因严重的恶心和虚脱症状而停止治疗。
在常规临床条件下，多佐胺作为单一药物和附加药物均有效。其疗效至少与口服乙酰唑胺相当。有时会出现局部药物反应，全身反应也会出现。
